Asunaprevir is a medication used to treat chronic hepatitis C virus (HCV) infection. It is a direct-acting antiviral (DAA) drug and acts by inhibiting the HCV NS3/4A protease. Asunaprevir is used in combination with other medications such as peginterferon alfa and ribavirin in adults with genotypes 1, 2, and 3 of HCV infection. It is available in tablets and is taken orally.
Asunaprevir, also known by the brand name Sunvepra in some regions, was an investigational drug for the treatment of hepatitis C. While it showed promise in clinical trials, it is not currently available and not recommended for use:
Intended use:
- Asunaprevir targeted the NS3 protease enzyme of the hepatitis C virus (HCV), specifically genotypes 1 and 4. This enzyme is essential for viral replication.
- It was intended to be used in combination with other medications for chronic hepatitis C in adults with compensated liver cirrhosis.
Development Status:
- Asunaprevir had promising results in Phase III clinical trials, particularly when combined with daclatasvir for genotype 1b.
- However, development was discontinued in 2017 due to the emergence of more effective and well-tolerated treatment options for hepatitis C.
Key points:
- Not commercially available: Asunaprevir is not currently prescribed and should not be used.
- Alternative treatments exist: Consult your doctor for information on current treatment options for hepatitis C.
Remember, consulting a healthcare professional is crucial for any questions or concerns regarding hepatitis C and its treatment.